FDA Reshapes Drug Testing Approach

The agency outlined early regulatory actions supporting nonanimal methods, including draft guidance, artificial intelligence tools, and expanded use of human-relevant data models.

By
Kathryn Wighton
April 20, 2026
2 min

MDSpire News

Objective:

To reduce animal testing in preclinical safety studies and advance alternative methods in drug development.

Approach:

Key Findings:

Animal models have limited predictive value, with over 90% of drugs deemed safe in animal studies failing in human trials.
The FDA's initiatives may improve drug safety predictions, shorten development timelines, and reduce animal testing reliance.

Interpretation:

The FDA's shift towards alternative testing methods aims to enhance drug safety and efficacy while minimizing animal use, reflecting a significant change in regulatory practices.

Limitations:

The long-term effectiveness of alternative methods in predicting human outcomes remains to be fully validated.
Transitioning to new methodologies may require additional training and resources for researchers.